How do I appeal an insurance denial for a GLP-1 medication?

Step 1: find the exact reason the plan gave

The notice must state the specific reasons for the determination, including the denial code and its corresponding meaning. See the most common GLP-1 insurance denial reasons for depth on each. Denials for 'not medically necessary', 'experimental or investigative', and 'not a covered benefit under your plan' can each be appealed; for 'not on the formulary', use the plan's drug exceptions process to get a prescribed drug that is not normally covered.

Preauthorization (also called prior authorization, prior approval, or precertification) is a plan's decision that a service, treatment plan, prescription drug, or durable medical equipment is medically necessary — not a promise the plan will cover the cost. A formulary is the list of prescription drugs a plan covers.

Step 2: request the criteria the plan actually used

The notice must describe the standard used to deny the claim and the internal guidelines or criterion used, with a copy of the internal requirements free of charge on request. If the denial rests on medical necessity, experimental treatment, or a similar exclusion, it must also provide the scientific or clinical judgment behind it, or state that explanation is free on request.

Ask in writing: claimants may obtain coding and other information relevant to their claim free on request under 29 CFR 2560.503-1(h)(2)(iii), and the notice must describe any additional information needed to improve or complete the claim. You also have the right to a full and fair review — to see and respond with written comments, documents, and records to any evidence or rationale under consideration.

Step 3: build the clinical case with your prescriber

Submit anything you want the insurer to consider, such as a letter from the doctor — see what documentation gets a GLP-1 prior authorization approved. For a formulary exception, the doctor must confirm to the plan, orally or in writing, that the drug is appropriate for your condition. Three grounds support an exception request: covered drugs have not been or will not be as effective; a covered alternative has caused or is likely to cause side effects harmful to you; or, where doses are limited, the allowed dosage has not worked.

Match the request to the approved indication — a mismatch is an easy denial to defend. Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Mounjaro's FDA-approved indication is limited to glycemic control in type 2 diabetes mellitus; chronic weight management is not an approved Mounjaro indication.

Form matters too. Wegovy comes in two dosage forms under one brand name and one FDA label — WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet — and prescribers must specify which, since dosing schedules and indications differ. Both forms are indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Zepbound is administered exclusively as a subcutaneous injection; its FDA label describes it only as 'injection, for subcutaneous use' and lists no oral form.

If the denial turns on BMI, the Zepbound weight-reduction registration trials used a BMI of 30 kg/m2 or greater for obesity, and 27 to less than 30 kg/m2 with at least one weight-related comorbid condition for overweight. Both Zepbound indications are limited to adults; safety and effectiveness are not established in pediatric patients.

Step 4: file the internal appeal and keep proof

File by completing all required forms, or by writing to the insurer with your name, claim number, and health insurance ID number — in writing except in urgent cases, where oral filing is acceptable. You or an authorized representative designated in writing may file, and your state's Consumer Assistance Program can file for you.

Keep a paper trail: the Explanation of Benefits forms or letters showing what was denied; a copy of your appeal request; a copy of any authorization you sign for someone else to file; and notes from phone calls with insurer or doctor — day, time, name, title, and what was said. Keep originals and submit copies, except the original appeal request and the original third-party authorization, which go to the insurer.

Decisions are due within 30 days for a service you have not yet received and 60 days for one you have. The group market may require one or two levels of internal appeal; the individual market has one. If the standard timeline would seriously jeopardize your life or ability to regain maximum function, file an expedited appeal: urgent-care appeals must be decided as quickly as your condition requires, and no later than 72 hours after the plan receives the request.

Throughout, appeal reviewers must not have conflicts of interest. Plans must also provide continued coverage pending the outcome of an appeal — a rule narrower than it sounds: it protects an ongoing course of treatment the plan has already approved, not a drug the plan never approved in the first place. The process ends with a written decision that must tell you how to request external review.

Step 5: if the denial stands, go to external review

External review hands the appeal to an independent third party — the insurance company no longer gets the final say — see what an external review is and when to request one. Any denial involving medical judgment is eligible, including determinations based on the plan's requirements for medical necessity, appropriateness, health care setting, level of care, or effectiveness of a covered benefit.

Your Explanation of Benefits or final internal denial lists the organization that will handle the review. Insurers in all states must offer an external review process meeting federal consumer protection standards; where a state's process falls short, HHS oversees the process for that state, and a plan participating in neither must contract with an independent review organization. The federal process is run by designated contractor MAXIMUS Federal Services, Inc., at no cost to plan, consumer, or authorized representative; its decisions are final and binding on claimant and plan alike, except where other remedies exist under federal or state law, such as a lawsuit.

One current disruption: as of July 1, 2026, the HHS-Administered Federal External Review Process (FERP) is temporarily unavailable for enrollees in Alabama, Florida, Georgia, Texas, Wisconsin, or a U.S. territory other than Puerto Rico whose plan or issuer uses that process; otherwise follow the instructions in the notice from your plan or issuer. HHS states it is working on a solution and will provide more information about extending deadlines for eligible requesters.

Cost and speed: external review is free under the federal process, and the plan or issuer — not you — pays the independent review organization. Only states that expressly allowed a filing fee as of November 18, 2015 may still charge one. As of October 2025, such a fee must not exceed $25 per review, must be refunded if the denial is reversed, must be waived for undue financial hardship, and is capped at $75 per claimant per plan year. Standard external reviews are decided no later than 45 days after the request; expedited reviews within 72 hours or less, depending on medical urgency.

The insurer is required by law to accept the external reviewer's decision; if the denial is overturned, the insurer must provide the payments or services requested. No review organization or clinical reviewer may have a material, professional, familial, or financial conflict of interest with the issuer, claimant, or provider. Nor must you always finish the internal process first: an internal appeal is deemed exhausted when the plan waives it, in urgent-care situations, or when the plan fails to comply with the internal appeals requirements; in urgent situations you may request external review at the same time as the internal appeal.

If your plan excludes weight-management drugs

Not every appeal will win — start with whether insurance covers GLP-1 weight loss medications at all. The exceptions process still helps: while you are in it, the plan may give you access to the requested drug until a decision is made, and if an exception is granted the plan generally treats the drug as covered, charges the copayment tier of the most expensive drugs already covered, and counts what you pay toward your deductible and maximum out-of-pocket limits.

Medicare is different from the start: since the Part D program's inception, CMS has interpreted the statutory exclusion of 'agents when used for weight loss' to mean anti-obesity medications are coverable under Part D only for a medically accepted indication other than weight loss or weight management. Separately, eligible Part D beneficiaries can get certain GLP-1s, including Zepbound, for a $50 per month copay through the Medicare GLP-1 Bridge, a short-term demonstration running July 1, 2026 through December 31, 2027 — Zepbound KwikPen only; the single-dose vial and single-dose pen are not included.

If coverage does not come through, cash pay remains: as of August 2026, Measured's cash pay programs start at $119/month with medication and membership included. Compounded medications are not reviewed or approved by the FDA for safety or effectiveness, and Measured membership fees are not covered by insurance and are paid separately.

Where Measured fits

For patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the plan, and states that many plans require prior authorization before covering brand-name GLP-1s such as Ozempic, Wegovy, Mounjaro, or Zepbound. Its insurance concierge team submits prior authorizations on the patient's behalf and keeps the patient updated; membership includes insurance benefit verification and prior authorization support, when applicable, and Measured states that if prior authorization is approved, the patient pays only their plan's copay at the pharmacy.

Whether a plan covers a given GLP-1 depends on its own terms; nothing here predicts your appeal's outcome.

---

Last reviewed: August 5, 2026. This article describes federal appeal rights and timelines and is not medical advice.